NASDAQ:BCLI Brainstorm Cell Therapeutics Q3 2026 Earnings Date & Estimates $0.81 +0.03 (+4.12%) As of 12:13 PM Eastern Brainstorm Cell Therapeutics is estimated to report Q3 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings History Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 16, 2026Conference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Brainstorm Cell Therapeutics in Q3 2026Brainstorm Cell Therapeutics is expected to post earnings of -$0.18 per share. Brainstorm Cell Therapeutics last reported on August 14, 2026, posting -$0.35 per share and missing the -$0.29 consensus estimate. Brainstorm Cell Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.18Recent Track RecordLast ReportedAug 14, 2026Last Quarter EPS-$0.35 (Missed by -$0.06)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileAug 2026 Earnings ReportQ1 2025 Earnings ReportQ2 2024 Earnings Report Brainstorm Cell Therapeutics Q3 2026 Earnings FAQ When does Brainstorm Cell Therapeutics report Q3 2026 earnings? Brainstorm Cell Therapeutics (NASDAQ:BCLI) is estimated to report Q3 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Brainstorm Cell Therapeutics' Q3 2026 earnings call? Brainstorm Cell Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Brainstorm Cell Therapeutics? Analysts expect Brainstorm Cell Therapeutics to post earnings of -$0.18 per share for Q3 2026. Brainstorm Cell Therapeutics Earnings HeadlinesBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Break Above 200-Day Moving Average - Here's What HappenedOctober 9, 2026 | americanbankingnews.comBrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsAugust 24, 2026 | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 19 at 1:00 AM | Porter & Company (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Brainstorm Cell Therapeutics (OtherBCLI) and Edwards Lifesciences (EW)August 20, 2026 | theglobeandmail.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deBrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14, 2026 | prnewswire.comSee More Brainstorm Cell Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Brainstorm Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your email. Email Address About Brainstorm Cell TherapeuticsBrainstorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s proprietary NurOwn platform uses a patient’s own bone marrow-derived mesenchymal stem cells, which are expanded and induced to secrete neurotrophic factors and other proteins intended to support the survival and function of nerve cells. BrainStorm’s lead candidate, NurOwn, has primarily been studied as a potential treatment for amyotrophic lateral sclerosis (ALS). The company has also investigated the platform in other disorders, including progressive multiple sclerosis and Parkinson’s disease. Its activities include clinical development, manufacturing-process development, regulatory work and research into additional applications for its cellular technology. Founded in Israel, BrainStorm Cell Therapeutics has conducted development activities in the United States and internationally through clinical studies and regulatory interactions. The company continues to focus on advancing its NurOwn platform and evaluating potential therapies for serious neurological conditions for which treatment options remain limited.View Brainstorm Cell Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Meta Claims Frontier-Class AI Status With New Muse Wonder ModelsMicrosoft's New AI Chip Could Change the Economics of AI Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
